3Glen P,Jamieson NB,McMillan DC,et al.Evaluation of an inflammation-based prognostic score in patients with inoperablepancreatic cancer[J].Pancreatology,2006,6(5):450.
4Ulla RJL,Alvarez SMV,Paz EJ,et al.Evaluation of the biliopancreatic region suing endoscopic ultrasonography in patients referredwith andwithoutabdominalpain andCA19-9 serum levelelevation[J].JOP,2007,8(2):191.
5Handschumacher RE,Harding MW,Rice J,et al.Cyclophilin:a specific cytosolic binding protein for cyclosporin A[J].Science,1984,226:544.
6Howard BA,Zheng Z,Campa MJ,et al.Translating biomarkers into clinical practice:prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer[J].Lung Cancer,2004,46:313.
7Campa MJ,Wang MZ,Howard B,Fitzgerald MC,Patz EF Jr.Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer[J].Cancer Res,2003,63:1652.
8Choi KJ,Piao YJ,Lim MJ,et al.Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia-and cisplatin-induced cell death[J].Cancer Res,2007,67:3654.
9Melle C,Osterloh D,Ernst G,Schimmel B,Bleul A,von Eggeling F.Identification of proteins from colorectal cancer tissue by two-dimensional gel electrophoresis and SELDI mass spectrometry[J].Int J Mol Med,2005,16:11.
10Zhou JR,Fu ZX,Wei LZ,Li YP,Li JC.Identification of tumor-associated proteins in laryngeal squamous cell carcinoma by proteomics[J].Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,2007,42:934.
同被引文献15
1Duraker N, Hot S, Polar Y, et al. CEA. CA 19-9. and CAI25 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice [J]. J Surg Oncol, 2007, 95 (2) : 142-147.
2Koom WS, Seong J, Kim YB, et al. CA19-9 as a predict or for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy [J]. In t J Radiat Oncol Biol Phys, 2009, 73 (4): 1148-1154.
3Tsavaris N, Kosmas C, Papadoniou N, et al. CEA and CA19-9 serum tumor markers as prognostic factors in patients with locally advanced (urtreseetable) or metastatic pancreatic adenoearcinoma: aretros pective analysis [J]. J Chemother, 2009, 21 (6) : 673- 680.
4Duffy M J, Sturgeon C, Lamerz R, et al. Tumor marker-s in pancreatic cancer: a European Group on Tumor Markers (EGTM) statusreport [J] . Ann Oncol. 2010. 21 (3): 441-447.
